Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Shattuck Labs, Inc.
AbbVie
EpicentRx, Inc.
ImmunoGen, Inc.
Roswell Park Cancer Institute
National Cheng-Kung University Hospital
ImmunoGen, Inc.
Fox Chase Cancer Center
National Cancer Institute (NCI)
King Faisal Specialist Hospital & Research Center
SWOG Cancer Research Network
Vejle Hospital
UNC Lineberger Comprehensive Cancer Center